Kubota Pharmaceutical Holdings Co., Ltd.
4596.TJPXHealthcareBiotechnology
Latest quote
¥67.00
−¥1.00 · -1.47%
4596.T company overview
Regular session · JST · Market data may be delayed.
Company profile
Company websiteKubota Pharmaceutical Holdings Co., Ltd., an international entity established in Tokyo, Japan, in 2002, focuses on the creation and advancement of a diverse range of pharmaceutical treatments and medical devices. A primary asset in their development pipeline is emixustat hydrochloride, a drug currently undergoing Phase III clinical trials for Stargardt disease and Phase II trials for proliferative diabetic retinopathy. Beyond its pharmaceutical endeavors, the company is also innovating in medical technology, specifically with a patient-centric ophthalmology suite designed for remote retinal monitoring. This advanced suite features both miniature, home-use optical coherence tomography (OCT) devices and high-resolution OCT technology adapted from NASA. Furthermore, Kubota Pharmaceutical Holdings is developing a wearable device aimed at controlling myopia.
- Industry
- Biotechnology
- Sector
- Healthcare
- Headquarters
- JP
- CEO
- Ryo Kubota
- Listed since
- Dec 6, 2016
- Employees
- 8
Market position
Day range
Current ¥67.00
52-week range
Current ¥67.00
- Open
- ¥68.00
- Previous close
- ¥68.00
- Volume
- 559K
- 0.2× average
- Average volume
- 2.78M
- Average daily volume
- Market cap
- 9.4B JPY
- Beta
- 1.8
- Market reference 1
- 50-day average
- ¥64.00
- +4.69% above average
- 200-day average
- ¥82.54
- -18.83% below average
Financials
Financial snapshot
Latest / TTMValuation & yield
- Enterprise value
- 891.06M JPY
- P/E (TTM)
- -8.21×
- P/B (TTM)
- 6.19×
- P/S (TTM)
- 578.13×
- EV / EBITDA
- -1.04×
- Earnings yield
- -25.22%
- Free cash flow yield
- -22.07%
- Dividend yield
- 0.00%
Profitability & efficiency
- Gross margin
- -157.34%
- Operating margin
- -6634.39%
- Net margin
- -5389.13%
- Return on equity
- -37.28%
- Return on assets
- -34.16%
- Return on invested capital
- -44.21%
Financial health
- Debt / equity
- 0.01×
- Current ratio
- 12.51×
- Altman Z-score
- 13.91
- Piotroski F-score
- 1 of 9
Financial statements
Margin trends
Profitability as a percentage of reported revenue.
Income trends
Revenue
Operating income
Net income
| Metric (JPY) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 21.34M JPY | 27.19M JPY | 39.89M JPY | 8.25M JPY | — |
| Cost of goods sold | 24.47M JPY | 70.8M JPY | 98.93M JPY | 64.8M JPY | 59.24M JPY |
| Gross profit | −3.13M JPY | −43.61M JPY | −59.05M JPY | −56.54M JPY | −59.24M JPY |
| Research and development | 312.21M JPY | 543.84M JPY | 788.79M JPY | 1.51B JPY | 2.04B JPY |
| Selling, general, and administrative | 542.99M JPY | 644.87M JPY | 545.68M JPY | 542.32M JPY | 544.67M JPY |
| Operating expenses | 855.21M JPY | 1.19B JPY | 1.33B JPY | 2.06B JPY | 2.59B JPY |
| Interest income | 1.85M JPY | 5.73M JPY | 13.91M JPY | 18.46M JPY | 11.24M JPY |
| Interest expense | 872K JPY | 7.4M JPY | 9.37M JPY | 11.56M JPY | 18.17M JPY |
| Depreciation and amortization | — | 65.65M JPY | 87.16M JPY | 58.97M JPY | 59.24M JPY |
| Operating income | −858.34M JPY | −1.23B JPY | −1.39B JPY | −2.11B JPY | −2.64B JPY |
| Net income | −676.25M JPY | −1.33B JPY | −1.49B JPY | −2.02B JPY | −2.62B JPY |
Company facts updated Aug 24, 2026.
Earnings
- Latest EPS result
- -2.32
EPS: actual versus estimate
Recent quarterly results
Revenue: actual versus estimate
Recent quarterly results
4596.T peers
Continue in GoAI
Research 4596.Tresearch.disclaimer